Phase I clinical trial of TO-206 - Safety trial in patients with Japanese cedar pollinosis -

Status

Unknown

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080222215

Enrollment

Registered

2013-09-06

Start date

2013-09-06

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Japanese cedar pollinosis

Interventions

investigational material(s) Generic name etc : TO-206 INN of investigational material : Therapeutic category code : 449 Other antiallergic agents Dosage and Administration for Investigational materia

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: 1)Patients with specific IgE against cedar pollen CAP class 3 or more 2)Positive skin prick test against cedar pollen 3)Patients who have a clinical history of cedar pollinosis in 2012 and 2013 cedar pollen seasons

Exclusion criteria

Exclusion criteria: 1)Patients with perennial allergic rhinitis, medication-derived rhinitis, vasomotor rhinitis or non-allergic rhinitis during therapy 2)Patients who have developed asthmatic attack within 5 years before the pre-treatment observation visit 3)Patients who have received specific immunotherapy for cedar pollinosis in history

Design outcomes

Primary

Measure	Time frame
Safety	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026